CDK2

Cyclin-dependent kinase 2

506,058 patent compounds predicted against CDK2, 292,414 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL21169	0.55	19/20
SCHEMBL20693	0.53	19/20
SCHEMBL19015	0.51	19/20
SCHEMBL31357	0.50	18/20
SCHEMBL31358	0.50	18/20
SCHEMBL12466	0.58	16/20
Methylguanine (SCHEMBL34851)	0.51	16/20
SCHEMBL12292	0.59	15/20
Alvocidib (SCHEMBL3651)	1.00	14/20
Alvocidib (SCHEMBL3652)	1.00	14/20
Purvalanol B (SCHEMBL27951)	1.00	13/20
2,6-Diaminopurine (SCHEMBL24053)	0.66	11/20
SCHEMBL21483	0.56	11/20
SCHEMBL20332	0.52	11/20
SCHEMBL29182	0.52	11/20
SCHEMBL20155	0.51	11/20
SCHEMBL22364	0.50	11/20
Clonazepam (SCHEMBL38899)	0.59	10/20
SCHEMBL20761	0.52	10/20
SCHEMBL19840	0.51	10/20

Germline variants in CDK2 on Sugi Variant → ClinVar classifications, population frequency, and predictor agreement (AlphaMissense, SaProt, REVEL) Full CDK2 gene report on Sugi Atlas → Gene function, pathways, protein structure, constraint & interactions

Clinical trials — most relevant to CDK2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Clinical and Pharmacoeconomic Assessment of CDK4/6 Inhibitors for Treatment of Breast Cancer in Egypt	PHASE4	COMPLETED
A Phase 3 Study Comparing Dinaciclib Versus Ofatumumab in Patients With Refractory Chronic Lymphocytic Leukemia (P07714)	PHASE3	COMPLETED
Effect of Silymarin in Metastatic Colorectal Cancer Patients	PHASE3	UNKNOWN
Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC)	PHASE1/PHASE2	RECRUITING
Efficacy Study Of P276-00 In Subjects Of Malignant Melanoma Positive For Cyclin D1 Expression	PHASE2	COMPLETED
Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer	PHASE2	COMPLETED
TQB3616 Capsules Combined With Abiraterone Acetate Plus Prednisone in Metastatic Castration-Resistant Prostate Cancer	PHASE2	UNKNOWN
Study of AVZO-021 in Patients With Advanced Solid Tumors	PHASE1/PHASE2	RECRUITING
CDK 4/6 Inhibitor, Ribociclib, With Adjuvant Endocrine Therapy for ER-positive Breast Cancer	PHASE2	ACTIVE_NOT_RECRUITING
Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer	PHASE2	RECRUITING
Abemaciclib in Patients With HIV-associated and HIV-negative Kaposi Sarcoma	PHASE1/PHASE2	RECRUITING
Study of AZD1775 in Combination With Paclitaxel, in Advanced Gastric Adenocarcinoma Patients Harboring TP53 Mutation as a Second-line Chemotherapy	PHASE2	COMPLETED
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6	PHASE2	RECRUITING
Palbociclib With Everolimus + Exemestane In BC	PHASE1/PHASE2	COMPLETED
An Open-Label, Phase Ib/II Clinical Trial Of Cdk 4/6 Inhibitor, Ribociclib (Lee011), In Combination With Trastuzumab Or T-Dm1 For Advanced/Metastatic Her2-Positive Breast Cancer.	PHASE1/PHASE2	COMPLETED
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas	PHASE2	RECRUITING
Histology-Independent Study of Palbociclib in Patients With Advanced Cancer	PHASE2	WITHDRAWN
Avelumab, Palbociclib and Axitinib in Advanced RCC	PHASE2	WITHDRAWN
Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in HR-positive, HER2-positive Metastatic Breast	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING
Cyclin Dependent Kinase (CDK)4/6 Inhibitor, PD0332991 in Advanced Non-small Cell Lung Cancer NSCLC.	PHASE2	COMPLETED
AZD1775 for Advanced Solid Tumors	PHASE1	COMPLETED
Open Label Phase I Study of P276-00 in Patients With Advanced Refractory Neoplasms	PHASE1	COMPLETED
TSL2109 Capsules in Advanced Solid Tumor Patients: Safety, Tolerability, PK and Preliminary Efficacy	PHASE1	RECRUITING
Dinaciclib, Bortezomib, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma	PHASE1	COMPLETED
Study of PHA-848125AC in Adult Patients With Advanced/Metastatic Solid Tumors	PHASE1	COMPLETED
Study of FCN-437c in Patients With Advanced Solid Tumors	PHASE1	COMPLETED
Ilorasertib in Treating Patients With CDKN2A-deficient Advanced or Metastatic Solid Cancers That Cannot Be Removed by Surgery	PHASE1	COMPLETED
Study Of Real-World Evidence In Patients Treated With Palbociclib During a 2.5 Years Follow-Up Period	nan	UNKNOWN
Incidence of Venous Thromboembolism and Cardiovascular Events in Breast Cancer Patients Undergoing Cyclin-dependent Kinase 4/6 Inhibitors: The Breast Cancer Associated Vascular Events During Cyclin-dependent Kinase 4/6 Inhibitors Therapy (BRAVE-Cyclin) Study	nan	ACTIVE_NOT_RECRUITING
Advanced Breast Cancer Study of CDK4/6 Inhibitor Combined With Endocrine Therapy Endocrine Therapy in HR+/HER2- Advanced Breast Cancer	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a CDK2 binder may also engage these)

Protein	Name	Similarity
Q5E9Y0	—	1.000	Q5E9Y0 →
P48963	—	1.000	P48963 →
Q63699	—	1.000	Q63699 →
O55076	—	1.000	O55076 →
P23437	—	1.000	P23437 →
P43450	—	1.000	P43450 →
P51166	—	0.999	P51166 →
CDK3	Cyclin-dependent kinase 3	0.999	landscape →
P23111	—	0.999	P23111 →
Q80YP0	—	0.998	Q80YP0 →
P29619	—	0.998	P29619 →
Q9W739	—	0.997	Q9W739 →
P24100	—	0.997	P24100 →
Q05006	—	0.997	Q05006 →
Q5RCH1	—	0.997	Q5RCH1 →
Q03114	—	0.997	Q03114 →
Q41639	—	0.996	Q41639 →
Q38773	—	0.996	Q38773 →
Q2PQN9	—	0.996	Q2PQN9 →
Q9DGD3	—	0.996	Q9DGD3 →
P34112	—	0.996	P34112 →
Q26671	—	0.996	Q26671 →
P34117	—	0.995	P34117 →
P04551	—	0.995	P04551 →
Q38772	—	0.995	Q38772 →
P52389	—	0.994	P52389 →
CDK1	Cyclin-dependent kinase 1	0.994	landscape →
Q27032	—	0.994	Q27032 →
P24923	—	0.993	P24923 →
Q9DGA5	—	0.993	Q9DGA5 →